Quest Diagnostics Inc vs Remitly Global Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Remitly Global Inc trades at $23.5 (market cap $4.85B). The key difference: Quest Diagnostics Inc is far larger — about 5.2× Remitly Global Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Remitly Global Inc for 53 Days on average.
| DGX | RELY | |
|---|---|---|
Market Cap | $25.06B | $4.85B |
Volume | 927,361 | 2,599,081 |
Sector | Health | Technology |
52-Week High | $247.45 | $26.92 |
52-Week Low | $173.49 | $12.20 |
Typical Hold Time | 56 Days | 53 Days |
Enterprise Value | $30.82B | $4.22B |
Dividend Yield | 1.52% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
RELY trades at $23.52, up 1.38% today, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and turning profitable with a net income of $67.93M. Recent Q2 2026 earnings beat expectations with EPS of $0.93 versus $0.12 expected, and active customers surpassed 10 million. Positive cash flow trends and a partnership with Etsy highlight operational strength and growth initiatives.
The outlook for RELY is positive, supported by accelerating revenue growth, expanding profit margins, and strong analyst consensus with a $30.50 price target. Key risks include reliance on continued customer expansion, competitive pressures in digital payments, and market volatility. The stock presents an opportunity for growth investors given its earnings beats and bullish institutional sentiment, though execution on growth targets remains critical.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →